SHIELD study: a multicenter, open-label, single-arm trial to evaluate the safety, pharmacokinetics and antiviral activity of fostemsavir in combination with optimized background therapy (OBT) in children and adolescents with HIV who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class antiretroviral (ARV) resistance
SHIELD 研究：一项多中心、开放标签、单臂试验，旨在评估福斯特沙韦联合优化背景疗法 (OBT) 在对当前联合抗逆转录病毒疗法 (cART) 治疗失败且存在双重或三重抗逆转录病毒 (ARV) 耐药性的 HIV 感染儿童和青少年中的安全性、药代动力学和抗病毒活性。
期刊:BMC Infectious Diseases
影响因子:3
doi:10.1186/s12879-026-12806-9
Grasa, Carlos; Salvadori, Nicolas; Nardone, Alessandra; Than-In-At, Kanchana; Koblansky, Alicia; Parry, Chris; Thakkar, Nilay; Wang, Marcia; Giaquinto, Carlo; Rojo, Pablo; Cressey, Tim R
